Vnitr Lek 2011, 57(7-8):631-634

Anemia and chronic kidney failure

S. Štěpánková
Centrum kardiovaskulární a transplantační chirurgie Brno, ředitel doc. MUDr. Petr Němec, CSc.

Anaemia is a common manifestation of a chronic kidney failure. It is caused by a relative shortage of erythropoetine (EPO) and iron deficite with its metabolism defect. The most important factor in the pathogenesis of iron metabolism defects is hepcidin. Hepcidin maintains the iron homeostasis in the organism. The therapy of renal anaemia is based on the iron substitution and erythropoiesis stimulating agents (ESA) application. The most common reasons for the resistance to ESA are (after iron deficiency) inflammation and malnutrition.

Keywords: chronic kidney failure; iron deficiency; hepcidin; erythropoiesis stimulating agents

Received: May 6, 2011; Published: July 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štěpánková S. Anemia and chronic kidney failure. Vnitr Lek. 2011;57(7-8):631-634.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Singh AK, Coyne DW, Shapiro W et al. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71: 1163-1171. Go to original source... Go to PubMed...
    2. Park CH, Valore EV, Waring AJ et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810. Go to original source... Go to PubMed...
    3. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia in inflammation. Blood 2003; 102: 783-788. Go to original source... Go to PubMed...
    4. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica 2006; 91: 727-732. Go to PubMed...
    5. Ganz T, Nemeth E. Iron sequestration and anemie of inflammation. Semin Hematol 2009; 46: 387-393. Go to original source... Go to PubMed...
    6. Nemeth E, Valore EV, Territo M et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein. Blood 2003; 101: 2461-2463. Go to original source... Go to PubMed...
    7. Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure cell aplasia. J Am Soc Nephrol 2004; 15: 398-406. Go to original source... Go to PubMed...
    8. Verhelst D, Rossert J, Casadevall N et al. Treatment of antibody-mediated pure red cell aplasia. J Am Soc Nephrol 2003; 14: 27A.
    9. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and proinflammatory cytokines. Nephrol Dial Transplant 2002; 17 (Suppl II): 39-43. Go to original source... Go to PubMed...
    10. Singh AK, Szczech L, Tang KL et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. Go to original source... Go to PubMed...
    11. Drüeke TB, Locatelli F, Clyne N et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084. Go to original source... Go to PubMed...
    12. Pfeffer MA, Burdmann AE, Chen CY et al. A trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. N Engl J Med 2009; 361: 2019-2032. Go to original source... Go to PubMed...
    13. Goldsmith D, Al-Khoury S, Shah N et al. Anemia after renal transplantation - role of immunosuppressive drugs and a pathophysiological appraisal. Nephron Clin Pract 2006; 104: c69-c74. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.